Arlington Capital Partners (Arlington Capital), a Washington, DC-based private equity firm, has acquired Molecular Products Group.
Headquartered in Harlow, Essex, UK, Molecular Products is a manufacturer of advanced chemistry-based products serving the healthcare, defence and industrial markets. The Company primarily specialises in the manufacture and supply of chemical technologies for the treatment of breathable gases and is able to serve its global customer base out of its two primary manufacturing facilities in Harlow, Essex, UK and Boulder, CO.
Peter Manos, a Managing Partner at Arlington Capital, says: “We are excited to be partnering with CEO Troy Rhudy and his management team at Molecular Products to expand the Company’s unique position in the development of advanced chemistry-based applications for the healthcare and defence markets, which are key verticals for Arlington. Molecular Products continues Arlington’s long track record of investing in industry leading companies with technically differentiated and proven products in the market.”
Troy Rhudy, CEO of Molecular Products, says: “Arlington Capital and Molecular Products have a shared vision to build upon the Company’s reputation as a world-class specialty chemical manufacturing Company and we are looking forward to a period of transformational growth both through strategic acquisitions and organic growth.”
Chris Stallmann, a Vice President at Arlington Capital, says: “We look forward to supporting the Company’s continued expansion of their specialty chemical manufacturing capabilities and bringing to market its robust pipeline of technologically differentiated and innovative next generation air purification products."
